Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Densitom ; 22(2): 279-286, 2019.
Article in English | MEDLINE | ID: mdl-29661687

ABSTRACT

The historical concept that obesity protects against bone fractures has been questioned. Weight loss appears to reduce bone mineral density (BMD); however, the results in young adults are inconsistent, and data on the effects of weight loss on bone microstructure are limited. This study aimed to evaluate the impact of weight loss using an intragastric balloon (IGB) on bone density and microstructure. Forty obese patients with metabolic syndrome (mean age 35.1 ± 7.3 yr) used an IGB continuously for 6 mo. Laboratory tests, areal BMD, and body composition measurements via dual-energy X-ray absorptiometry, and volumetric BMD and bone microstructure measurements via high-resolution peripheral quantitative computed tomography were conducted before IGB placement and after IGB removal. The mean weight loss was 11.5%. After 6 mo, there were significant increases in vitamin D and carboxyterminal telopeptide of type 1 collagen levels. After IGB use, areal BMD increased in the spine but decreased in the total femur and the 33% radius. Cortical BMD increased in the distal radius but tended to decrease in the distal tibia. The observed trabecular bone loss in the distal tibia contributed to the decline in the total volumetric BMD at this site. There was a negative correlation between the changes in leptin levels and the measures of trabecular quality in the tibia on high-resolutionperipheral quantitative computed tomography. Weight loss may negatively impact bone microstructure in young patients, especially for weight-bearing bones, in which obesity has a more prominent effect.


Subject(s)
Bone Density , Cancellous Bone/diagnostic imaging , Cortical Bone/diagnostic imaging , Gastric Balloon , Obesity/therapy , Weight Loss , Absorptiometry, Photon , Adult , Collagen Type I/blood , Female , Femur/diagnostic imaging , Femur Neck/diagnostic imaging , Humans , Leptin/blood , Lumbar Vertebrae/diagnostic imaging , Male , Metabolic Syndrome/blood , Metabolic Syndrome/complications , Obesity/blood , Obesity/complications , Obesity/diagnostic imaging , Peptides/blood , Radius/diagnostic imaging , Tibia/diagnostic imaging , Tomography, X-Ray Computed , Treatment Outcome , Vitamin D/analogs & derivatives , Vitamin D/blood
2.
World J Gastroenterol ; 22(31): 7146-56, 2016 Aug 21.
Article in English | MEDLINE | ID: mdl-27610024

ABSTRACT

AIM: To compare expression of nicotinic cholinergic receptors (CHRNs) in healthy and squamous cell carcinoma-affected esophagus and determine the prognostic value. METHODS: We performed RT-qPCR to measure the expression of CHRNs in 44 esophageal samples from healthy individuals and in matched normal surrounding mucosa, and in tumors from 28 patients diagnosed with esophageal squamous cell carcinoma (ESCC). Next, we performed correlation analysis for the detected expression of these receptors with the habits and clinico-pathological characteristics of all study participants. In order to investigate the possible correlations between the expression of the different CHRN subunits in both healthy esophagus and tissues from ESCC patients, correlation matrices were generated. Subsequently, we evaluated whether the detected alterations in expression of the various CHRNs could precede histopathological modifications during the esophageal carcinogenic processes by using receiver operating characteristic curve analysis. Finally, we evaluated the impact of CHRNA5 and CHRNA7 expression on overall survival by using multivariate analysis. RESULTS: CHRNA3, CHRNA5, CHRNA7 and CHRNB4, but not CHRNA1, CHRNA4, CHRNA9 or CHRNA10, were found to be expressed in normal (healthy) esophageal mucosa. In ESCC, CHRNA5 and CHRNA7 were overexpressed as compared with patient-matched surrounding non-tumor mucosa (ESCC-adjacent mucosa; P < 0.0001 and P = 0.0091, respectively). Positive correlations were observed between CHRNA3 and CHRNB4 expression in all samples analyzed. Additionally, CHRNB4 was found to be differentially expressed in the healthy esophagus and the normal-appearing ESCC-adjacent mucosa, allowing for distinguishment between these tissues with a sensitivity of 75.86% and a specificity of 78.95% (P = 0.0002). Finally, CHRNA5 expression was identified as an independent prognostic factor in ESCC; patients with high CHRNA5 expression showed an increased overall survival, in comparison with those with low expression. The corresponding age- and tumor stage-adjusted hazard ratio was 0.2684 (95%CI: 0.075-0.97, P = 0.0448). CONCLUSION: Expression of CHRNs is homogeneous along healthy esophagus and deregulated in ESCC, suggesting a pathogenic role for these receptors in ESCC development and progression.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Esophageal Neoplasms/metabolism , Esophagus/chemistry , Receptors, Nicotinic/analysis , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Esophageal Neoplasms/mortality , Esophageal Squamous Cell Carcinoma , Female , Humans , Male , Middle Aged , Prognosis , RNA, Messenger/analysis , Receptors, Nicotinic/genetics
3.
J Laparoendosc Adv Surg Tech A ; 26(3): 168-73, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26844373

ABSTRACT

BACKGROUND: Obesity is a worldwide epidemic that is difficult to control with non-invasive treatments, which usually present poor results. In this context, the intragastric balloon (IGB) is an important tool that presents a mean body weight loss (BWL) estimated at approximately 12%, although individual responses are highly variable. OBJECTIVES: This study assesses whether there are factors that can predict responses to IGB therapy either before or early after placement of the device. MATERIALS AND METHODS: A total of 50 obese patients underwent insertion of IGB placed endoscopically, and patients were monitored for 6 months. The evaluated predictive factors involved general characteristics and psychological, social, and dyspeptic aspects, and the preliminary results obtained in the first month after balloon placement. RESULTS: The mean weight loss was 11.5%, and 48% of the participants presented BWL >10%. Among the factors analyzed before IGB placement, only advanced age (P = .04) and higher scores obtained in the social relationships domain of a shorter version of the World Health Organization's Quality of Life questionnaire (P = .02) were significant. Analysis of the factors evaluated after IGB placement revealed that the BWL amounts observed in week 2 (P = .001) and week 4 (P < .001) and the intensity of dyspeptic symptoms in week 2 (P < .001) were positive predictive factors. CONCLUSIONS: The assessment of predictive factors may help to manage patients with IGB.


Subject(s)
Gastric Balloon , Obesity/therapy , Weight Loss , Adult , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Quality of Life , Surveys and Questionnaires , Treatment Outcome
4.
Bone ; 59: 89-92, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24220493

ABSTRACT

The effects of obesity and metabolic syndrome (MS) on bone health are controversial. Furthermore, the relationship between body composition and bone quality has not yet been determined in this context. The aim of this study was to investigate the correlations between body composition and bone mineral density (BMD) and bone microstructure in obese individuals with MS. This cross-sectional study assessed 50 obese individuals with MS with respect to their body composition and BMD, both assessed using dual X-ray absorptiometry, and bone microarchitecture, assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT) of the distal tibia and radius. Several HR-pQCT measurements exhibited statistically significant correlations with lean mass. Lean mass was positively correlated with parameters of better bone quality (r: 0.316-0.470) and negatively correlated with parameters of greater bone fragility (r: -0.460 to -0.310). Positive correlations were also observed between lean mass and BMD of the total femur and radius 33%. Fat mass was not significantly correlated with BMD or any HR-pQCT measurements. Our data suggest that lean mass might be a predictor of bone health in obese individuals with MS.


Subject(s)
Adipose Tissue , Body Composition , Bone Density , Bone and Bones/pathology , Metabolic Syndrome/complications , Obesity/complications , Adipose Tissue/anatomy & histology , Adult , Bone and Bones/anatomy & histology , Bone and Bones/diagnostic imaging , Female , Humans , Male , Metabolic Syndrome/diagnostic imaging , Metabolic Syndrome/physiopathology , Multivariate Analysis , Obesity/diagnostic imaging , Obesity/physiopathology , Organ Size , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...